“`html
Tempus AI (TEM) reported a 75% year-over-year revenue growth for Q1 2025, fueled by an 89% increase in genomics revenues. The company has established a landmark $200 million partnership with AstraZeneca (AZN) and Pathos to create the world’s largest oncology foundation model, enhancing its role in drug discovery and diagnostics.
NVIDIA (NVDA) is expanding its healthtech footprint through strategic partnerships with firms like Novo Nordisk (NVO) and DCAI. Year-to-date, Tempus AI’s shares have risen 91.8%, compared to NVIDIA’s 29.2%. Currently, Tempus is trading at a forward price-to-sales (P/S) ratio of 7.84, while NVIDIA’s is at 18.96.
Both companies hold a Zacks Rank #3 (Hold), indicating solid outlooks. Analysts suggest a potential average price increase of 5.3% for Tempus from its last closing price of $63.34 and 5.1% for NVIDIA from $173.74.
“`
